Omer Iftikhar
Interventional Cardiology · Slidell, LANPI 1861832073
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Medtronic at 28.4% of the total. Reporting peaked in 2022 at $9,039 and has fallen 67.7% since, to $2,917 in 2025.
Across 247 payments — averaging $88.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Penumbra, Inc.$4K
- Boston Scientific$3K
- Edwards Lifesciences$2K
- Abbott$2K
- W. L. Gore & Associates, Inc.$933
- plus $3K from 24 others
What the payments were for
- Travel & lodging$12,61058%
- Food & beverage$8,81140%
- Education$4182%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 82 | $6,206 |
| Penumbra, Inc. | 12 | $4,325 |
| Boston Scientific | 23 | $3,388 |
| Edwards Lifesciences | 18 | $2,136 |
| Abbott | 24 | $1,736 |
| W. L. Gore & Associates, Inc. | 2 | $933 |
| Inari Medical, Inc. | 3 | $304 |
| Amgen | 11 | $287 |
| Shockwave Medical, Inc | 5 | $272 |
| Cardiovascular Systems Inc. | 3 | $258 |
| Endologix LLC | 1 | $257 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $249 |
| Philips North America LLC | 4 | $245 |
| E.r. Squibb & Sons, L.L.C. | 12 | $175 |
| Stryker | 2 | $164 |
| Kestra Medical Technology Services, Inc. | 3 | $139 |
| Baxter Healthcare | 3 | $129 |
| Novartis | 6 | $102 |
| Irhythm Technologies, Inc. | 5 | $94 |
| Biotronik Inc. | 2 | $84 |
| Merck | 3 | $57 |
| Novo Nordisk | 3 | $53 |
| Boehringer Ingelheim | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $36 |
| Acist Medical Systems, Inc. | 1 | $34 |
| Johnson & Johnson(2 entities) | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Surmodics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$4,216
- VersaCross Access Solution$2,699
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,578
- COREVALVE EVOLUT R$1,299
- Advisa$1,082
- Omnilink Elite vascular stent system$973
- GORE CARDIOFORM Septal Occluder$933
- Micra$691
- Resolute$334
- ENDOCROSS Device$257
- Torus Stent Graft System$257
- WATCHMAN Access System$236
- CoreValve Evolut$222
- Integrity$210
- Ensite Cardiac Mapping System$208
- FLOWTRIEVER CATHETER, S$200
- CT THROMBECTOMY SYSTEM KIT$200
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$173
- (6571) Eagle Eye$148
- FlowTriever$139
How this compares
$21,839 in reported general payments places this provider in the 70th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 110 | $105,529 |
| XareltoRivaroxaban | 26 | $21,745 |
| Repatha SureclickEvolocumab | 26 | $21,618 |
| EntrestoSacubitril/Valsartan | 17 | $17,036 |
| Colchicine | 17 | $1,616 |
| Metoprolol Succinate | 137 | $1,351 |
| Atorvastatin Calcium | 142 | $1,253 |
| Ezetimibe | 95 | $1,211 |
| ClopidogrelClopidogrel Bisulfate | 49 | $435 |
| Carvedilol | 65 | $406 |
| Lisinopril | 66 | $405 |
| Rosuvastatin Calcium | 36 | $399 |
| Amlodipine Besylate | 73 | $391 |
| Losartan Potassium | 40 | $371 |
| Cilostazol | 22 | $361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $30 | $21,74526 claims |
| NovartisEntresto | $102 | $17,03617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Slidell
- Sergio BarriosSlidell$15K
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Rajan PatelNew Orleans$517K
- Agostino IngraldiLafayette$315K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
- Louis SalvaggioLafayette$214K
- Pradeep NairHouma$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.